Repligen Corp. 10-Q Summary: Quarter Ended June 30, 2002
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2002. Repligen Corporation is a biotechnology company focused on developing therapeutic products for pediatric diseases (autism, neurological/metabolic diseases, immune disorders) while generating revenue from specialty pharmaceutical products, specifically Protein A and SecreFlo (synthetic porcine secretin). The company recently relocated its headquarters to Waltham, Massachusetts, in May 2002.
Key Financial Metrics
| Metric | Q2 2002 | Q2 2001 |
|---|---|---|
| Product Revenue | $1,619,442 | $712,536 |
| Gross Margin | 59% | 50% |
| Net Loss | $(991,139) | $(1,343,509) |
| Loss Per Share (Basic/Diluted) | $(0.04) | $(0.05) |
| Cash and Cash Equivalents | $8,755,545 | $12,088,869 |
| Total Marketable Securities | $13,032,252 | N/A |
| Working Capital | $16,785,041 | N/A |
| Debt | None reported | None reported |
Note: Total Marketable Securities includes $10,830,208 in current and $2,202,044 in long-term securities. The company has no long-term debt but holds a $500,000 restricted cash balance for a lease letter of credit.
Material Changes vs. Prior Period
- Revenue Growth: Product revenue increased 127% year-over-year, driven by the timing of large-scale Protein A production orders.
- Expense Trends: Total costs and expenses rose 16% to $2.78 million. Research and Development (R&D) expenses decreased 14% due to lower clinical material costs. However, Selling, General, and Administrative (SG&A) expenses increased 43% due to litigation defense costs and expenses related to the headquarters relocation.
- Investment Income: Investment and interest income declined 51% to $168,579, attributed to lower average funds available for investment and reduced interest rates.
- Geographic Shift: Revenue mix shifted significantly; European sales accounted for 74% of revenue in Q2 2002 compared to 11% in Q2 2001, while U.S. sales dropped from 87% to 25%.
- Customer Concentration: In Q2 2002, two customers accounted for 54% and 20% of revenues, respectively. In the prior year, one customer accounted for 72%.
Guidance, Outlook, and Risks
- Outlook: Management anticipates significantly higher costs in fiscal 2003 due to expanded R&D for clinical trials and the launch of SecreFlo. The company believes it has sufficient funding for the next 24 months but may need to secure additional financing.
- SecreFlo Milestone: Following FDA approval of SecreFlo in April 2002, the company paid a $1.25 million cash milestone and recorded a $2.58 million non-cash liability for stock to be issued to ChiRhoClin, Inc. in October 2002.
- Legal Proceedings:
- Pro-Neuron Litigation: Pro-Neuron, Inc. sued Repligen and the University of California to void a license agreement regarding uridine for mitochondrial disease. Repligen intends to defend vigorously.
- BMS Patent Dispute: Repligen and the University of Michigan are litigating against Bristol-Myers Squibb (BMS) regarding inventorship of patents covering CTLA4-Ig. Failure to obtain shared ownership could restrict commercialization.
- Accounting Change: Arthur Andersen LLP was dismissed as independent accountants; Ernst & Young LLP was engaged for the fiscal year ending March 31, 2003.
Investor Verification Checklist
- Verify the status of the Pro-Neuron litigation and potential impact on the uridine therapeutic program.
- Confirm the timeline and regulatory status for the human secretin diagnostic application, which triggers additional milestone payments.
- Monitor the execution of the $2.58 million stock issuance to ChiRhoClin, Inc. in October 2002.
- Assess the sustainability of the 74% revenue concentration in Europe versus the historical U.S. dominance.
- Review the impact of the new Waltham facility lease on future operating expenses (estimated $230,000 annual increase).